Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta

Epilepsia

Volumn 38, Issue 3, 1997, Pages 309-316

  Pienimaki P ^a   Lampela, E ^a   Hakkola, J ^a   Arvela, P ^a   Raunio, H ^a   Vahakangas K ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Carbamazepine melabolites; Cytochrome P 450; Human placental perfusion; Oxcarbazepine metabolites

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE;

ANTICONVULSANT THERAPY; ARTICLE; DRUG METABOLISM; DRUG TRANSPORT; EPILEPSY; HUMAN; HUMAN TISSUE; PLACENTA PERFUSION; PRIORITY JOURNAL;

ANTICONVULSANTS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; FETAL BLOOD; HUMANS; MIXED FUNCTION OXYGENASES; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0942265500     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01122.x     Document Type: Article

References (49)

1. Pelkonen O. Fetoplacental biochemistry: xenobiotic metabolism and pharmacokinetics. In: Hemminki K, Sorsa M, Vainio H, eds. Occupational hazards and reproduction. Washington, DC: Hemisphere, 1985;113-26.
2. Derewlany LO, Knie B, Koren G. Human placental transfer and metabolism of p-aminobenzoic acid. J Pharmacol Exp Ther 1994;269:761-5.
3. Omarini D, Pistotti V, Bonati M. Placental perfusion: an overview of the literature. J Pharmacol Toxicol Meth 1992;28:61-6.
4. Faigle JW, Feldmann KF. Carbamazepine biotransformation. In: Woodbury DM, Penry JK, Pippenger CE, eds. Antiepileptic drugs. New York: Raven Press, 1982:483-95.
5. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacokinetic aspects. Clin Pharmacokinet 1985;10:80-90.
6. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994;47:355-60.
7. Johannessen SI. Pharmacokinetics of anti-epileptic drugs and their clinical significance. Behav Neural 1990;3(suppl 1):1-13.
8. Kerr BM, Levy RH. Carbamazepine, carbamazepine epoxide. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:529-41.
9. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6.
10. Glatt HR, Oesch F, Frigerio A, Grattini S. Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity. Int J Cancer 1975;16:787-97.
11. Castrén K, Pienimäki P, Arvela P, Vähäkangas K. Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. Hum Exp Toxicol 1996;15:577-82.
12. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
13. 14C-oxcarbazepine in man. Xenobiotica 1986;16:769-78.
14. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990;3(suppl 1):21-30.
15. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43:873-88.
16. Faigle JW, Menge GP. Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int Clin Psychopharmacol 1990;5(suppl 1):73-82.
17. Jensen PK. Oxcarbazepine (Trileptal) in antiepileptic polytherapy. Behav Neurol 1990;3(suppl 1):35-9.
18. Dam M, Østergaard LH. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:987-95.
19. Pienimäki P, Hartikainen A-L, Arvela P, et al. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995;36:241-8.
20. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol 1972;114:822-8.
21. Challier J-C. Criteria for evaluating perfusion experiments and presentation of results. In: Schneider H, Dancis J, eds. In vitro perfusion of human placental tissue. Contrib Gynecol Ohstet 1985;13:32-9.
22. Pienimäki P, Fuchs S, Isojärvi J, Vähäkangas K. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high performance liquid chromatography. J Chromatograph B 1995;673:97-105.
23. Henderson GI, Hu Z-Q, Johnson RF, Perez AB, Yang Y, Schenker S. Acyclovir transport by the human placenta. J Lab Clin Med 1992;120:885-92.
24. Pelkonen O, Pasanen M. Effect of heparin on the subcellular distribution of human placental 7-ethoxycoumarin O-deethylase activity. Biochem Pharmacol 1981;30:3254-6.
25. Neben DW, Gelboin HV. Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. I. Assay and properties of induced enzyme. J Biol Chem 1968;243:6242-9.
26. Burke MD, Prough RA, Mayer RT. Characteristics of a microsomal cytochrome P-448-mediated reaction: ethoxyresorufin O-deethylation. Drug Metab Dispos 1977;5:1-8.
27. Waxman DJ, Ko A, Walsh C. Radioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome P-450 isozymes purified from phenobarbital induced rat liver. J Biol Chem 1983;258:11937-47.
28. Hakkola J, Pasanen M, Hukkanen J, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996;51:403-11.
29. Kaufmann P. Influence of ischemia and artificial perfusion on placental ultrastructure and morphometry. In: Schneider H, Dancis J, eds. In vitro perfusion human placental tissue. Contrib Gynecol Obstet 1985;13:18-26.
30. Theisohn M, Heimann G. Disposition of antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol 1982;22:545-51.
31. Feldmann KF, Dörhöfer G, Faigle JW, Imhof P. Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers. In: Dam M, Gram L, Penry JK, eds. Advances in Epileptology: XIIth Epilepsy International Symposium, New York: Raven Press, 1981:89-96.
32. Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time- dependent changes: autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986;26:459-62.
33. Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987;28:286-94.
34. Regnaud L, Sirois G, Chakrabarti S. Effect of four-day treatment with carbamazepine at different dose levels on microsomal enzyme induction, drug metabolism and drug toxicity. Pharmacol Toxicol 1988;62:3-6.
35. Kaelin AC, Cummings AJ. A survey of aryl hydrocarbon hydroxylase activity in human placental homogenates. Placenta 1983;4:471-8.
36. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986;6:177-98.
37. Piafsky KM, Rane A. Formation of carbamazepine epoxide in human fetal liver. Drug Metab Dispos 1978;6:502-3.
38. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989;37:69-74.
39. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptics patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993;36:366-8.
40. Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharm Drug Dispos 1990;11:365-70.
41. Larkin JG, McKee PJW, Forrest F, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:65-71.
42. Hooper WD, Dickinson RG, Dunstan PR, Pendlebury SC, Eadie MJ. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. Clin Exp Neurol 1987;24:105-12.
43. Bülau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988;34:311-3.
44. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284-9.
45. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol 1986;31:91-4.
46. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-7.
47. Miller RK, Wier PJ, Shah Y, di Sant'Agnese PA, D'Gregorio RP. Criteria for in vitro dual perfusions in the human placental lobule: perfusions in excess of 12 hours. In: Genbacev O, Klopper A, Beaconsfield R, eds. Placenta as a model and a source. New York: Plenum Press, 1989:27-38.
48. Miller RK, Wier PJ, Maulik D, di Sant'Agnese PA. Human placenta in vitro: characterization during 12 h of dual perfusion. In: Schneider H, Dancis J, eds. In vitro perfusion of human placental tissue. Contrib Gynecol Obstet 1985;13:77-84.
49. Schneider H, Malek A, Duft R, Bersinger N. Evaluation of an in vitro dual perfusion system for the study of placental proteins: energy metabolism. In: Genbacev O, Klopper A, Beaconsfield R, eds. Placenta as a model and a source. New York: Plenum Press, 1989:39-50.